[ 1 ] Inoue S, Kitajima K. KDN (deaminated neuraminic acid): dreamful past and exciting future of the newest member of the sialic acid family. Glycoconj J 2006;23(5–6):277–90. link1

[ 2 ] Schauer R, Kamerling JP. Exploration of the sialic acid world. Adv Carbohydr Chem Biochem 2018;75:1–213. link1

[ 3 ] Kanamori A, Inoue S, Iwasaki M, Kitajima K, Kawai G, Yokoyama S, et al. Deaminated neuraminic acid-rich glycoprotein of rainbow trout egg vitelline envelope. Occurrence of a novel alpha-2,8-linked oligo(deaminated neuraminic acid) structure in O-linked glycan chains. J Biol Chem 1990;265 (35):21811–9. link1

[ 4 ] Kitazume S, Kitajima K, Inoue S, Troy 2nd FA, Cho JW, Lennarz WJ, et al. Identification of polysialic acid-containing glycoprotein in the jelly coat of sea urchin eggs. Occurrence of a novel type of polysialic acid structure. J Biol Chem 1994;269(36):22712–8. link1

[ 5 ] Miyata S, Sato C, Kitamura S, Toriyama M, Kitajima K. A major flagellum sialoglycoprotein in sea urchin sperm contains a novel polysialic acid, an a2,9- linked poly-N-acetylneuraminic acid chain, capped by an 8-O-sulfated sialic acid residue. Glycobiology 2004;14(9):827–40. link1

[ 6 ] Tezuka T, Taguchi T, Kanamori A, Muto Y, Kitajima K, Inoue Y, et al. Identification and structural determination of the KDN-containing N-linked glycan chains consisting of bi- and triantennary complex-type units of KDNglycoprotein previously isolated from rainbow trout vitelline envelopes. Biochemistry 1994;33(21):6495–502. link1

[ 7 ] Nadano D, Iwasaki M, Endo S, Kitajima K, Inoue S, Inoue Y. A naturally occurring deaminated neuraminic acid, 3-deoxy-D-glycero-D-galactononulosonic acid (KDN). Its unique occurrence at the nonreducing ends of oligosialyl chains in polysialoglycoprotein of rainbow trout eggs. J Biol Chem 1986;261(25):11550–7. link1

[ 8 ] Iwasaki M, Inoue S, Nadano D, Inoue Y. Isolation and structure of a novel deaminated neuraminic acid-containing oligosaccharide chain present in rainbow trout egg polysialoglycoprotein. Biochemistry 1987;26(5):1452–7. link1

[ 9 ] Song Y, Kitajima K, Inoue S, Inoue Y. Isolation and structural elucidation of a novel type of ganglioside, deaminated neuraminic acid (KDN)-containing glycosphingolipid, from rainbow trout sperm. The first example of the natural occurrence of KDN-ganglioside, (KDN)GM3. J Biol Chem 1991;266 (32):21929–35. link1

[10] Song Y, Kitajima K, Inoue S, Khoo KH, Morris HR, Dell A, et al. Expression of new KDN-gangliosides in rainbow trout testis during spermatogenesis and their structural identification. Glycobiology 1995;5(2):207–18. link1

[11] Kimura M, Hama Y, Sumi T, Asakawa M, Rao BN, Horne AP, et al. Characterization of a deaminated neuraminic acid-containing glycoprotein from the skin mucus of the loach, Misgurnus anguillicaudatus. J Biol Chem 1994;269(51):32138–43. link1

[12] Shashkov AS, Kosmachevskaya LN, Streshinskaya GM, Evtushenko LI, Bueva OV, Denisenko VA, et al. A polymer with a backbone of 3-deoxy-D-glycero-Dgalacto-non-2-ulopyranosonic acid, a teichuronic acid, and a b-glucosylated ribitol teichoic acid in the cell wall of plant pathogenic Streptomyces sp. VKM Ac-2124. Eur J Biochem 2002;269(24):6020–5. link1

[13] Shashkov AS, Tul’skaya EM, Evtushenko LI, Denisenko VA, Ivanyuk VG, Stomakhin AA, et al. Cell wall anionic polymers of Streptomyces sp. MB-8, the causative agent of potato scab. Carbohydr Res 2002;337(21–23):2255–61. link1

[14] Kawanishi K, Saha S, Diaz S, Vaill M, Sasmal A, Siddiqui SS, et al. Evolutionary conservation of human ketodeoxynonulosonic acid production is independent of sialoglycan biosynthesis. J Clin Invest 2021;131(5):e137681. link1

[15] Hao J, Vann WF, Hinderlich S, Sundaramoorthy M. Elimination of 2-keto-3- deoxy-D-glycero-D-galacto-nonulosonic acid 9-phosphate synthase activity from human N-acetylneuraminic acid 9-phosphate synthase by a single mutation. Biochem J 2006;397(1):195–201. link1

[16] Lawrence SM, Huddleston KA, Pitts LR, Nguyen N, Lee YC, Vann WF, et al. Cloning and expression of the human N-acetylneuraminic acid phosphate synthase gene with 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid biosynthetic ability. J Biol Chem 2000;275(23):17869–77. link1

[17] Inoue S, Lin SL, Chang T, Wu SH, Yao CW, Chu TY, et al. Identification of free deaminated sialic acid (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells. J Biol Chem 1998;273(42):27199–204. link1

[18] Inoue S, Poongodi GL, Suresh N, Chang T, Inoue Y. Identification and partial characterization of soluble and membrane-bound KDN(deaminoneuraminic acid)-glycoproteins in human ovarian teratocarcinoma PA-1, and enhanced expression of free and bound KDN in cells cultured in mannose-rich media. Glycoconj J 2006;23(5–6):401–10. link1

[19] Wang F, Xie B, Wang B, Troy 2nd FA. LC–MS/MS glycomic analyses of free and conjugated forms of the sialic acids, Neu5Ac, Neu5Gc and KDN in human throat cancers. Glycobiology 2015;25(12):1362–74. link1

[20] Inoue S, Kitajima K, Inoue Y. Identification of 2-keto-3-deoxy-D-glycero-Dgalactonononic acid (KDN, deaminoneuraminic acid) residues in mammalian tissues and human lung carcinoma cells: chemical evidence of the occurrence of KDN glycoconjugates in mammals. J Biol Chem 1996;271 (40):24341–4. link1

[21] Yabu M, Korekane H, Hatano K, Kaneda Y, Nonomura N, Sato C, et al. Occurrence of free deaminoneuraminic acid (KDN)-containing complex-type N-glycans in human prostate cancers. Glycobiology 2013;23(6):634–42. link1

[22] Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60(2):70–98. link1

[23] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71 (4):618–29. link1

[24] Llop E, Ferrer-Batallé M, Barrabés S, Guerrero PE, Ramírez M, Saldova R, et al. Improvement of prostate cancer diagnosis by detecting PSA glycosylationspecific changes. Theranostics 2016;6(8):1190–204. link1

[25] Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun 2014;448(4):390–6. link1

[26] Inoue T, Kaneko T, Muramatsu S, Kimura H, Yoshino T, Goto T, et al. LacdiNAcglycosylated prostate-specific antigen density is a potential biomarker of prostate cancer. Clin Genitourin Cancer 2020;18(1):e28–36. link1

[27] Kammeijer GSM, Nouta J, de la Rosette JJMCH, de Reijke TM, Wuhrer M. An indepth glycosylation assay for urinary prostate-specific antigen. Anal Chem 2018;90(7):4414–21. link1

[28] Wang W, Kałuza A, Nouta J, Nicolardi S, Ferens-Sieczkowska M, Wuhrer M, _ et al. High-throughput glycopeptide profiling of prostate-specific antigen from seminal plasma by MALDI-MS. Talanta 2021;222:121495. link1

[29] Ruhaak LR, Steenvoorden E, Koeleman CA, Deelder AM, Wuhrer M. 2-Picolineborane: a non-toxic reducing agent for oligosaccharide labeling by reductive amination. Proteomics 2010;10(12):2330–6. link1

[30] Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, Wuhrer M. Glycan labeling strategies and their use in identification and quantification. Anal Bioanal Chem 2010;397(8):3457–81. link1

[31] Zhang T, Madunic´ K, Holst S, Zhang J, Jin C, Ten Dijke P, et al. Development of a 96-well plate sample preparation method for integrated N- and O-glycomics using porous graphitized carbon liquid chromatography-mass spectrometry. Mol Omics 2020;16(4):355–63. link1

[32] Kammeijer GSM, Kohler I, Jansen BC, Hensbergen PJ, Mayboroda OA, Falck D, et al. Dopant enriched nitrogen gas combined with sheathless capillary electrophoresis–electrospray ionization–mass spectrometry for improved sensitivity and repeatability in glycopeptide analysis. Anal Chem 2016;88 (11):5849–56. link1

[33] Lageveen-Kammeijer GSM, de Haan N, Mohaupt P, Wagt S, Filius M, Nouta J, et al. Highly sensitive CE–ESI–MS analysis of N-glycans from complex biological samples. Nat Commun 2019;10(1):2137. link1

[34] Wojcik I, Sénard T, de Graaf EL, Janssen GMC, de Ru AH, Mohammed Y, et al. Site-specific glycosylation mapping of Fc gamma receptor IIIb from neutrophils of individual healthy donors. Anal Chem 2020;92 (19):13172–81. link1

[35] Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res 2008;7(4):16509. link1

[36] Cooper CA, Gasteiger E, Packer NH. GlycoMod—a software tool for determining glycosylation compositions from mass spectrometric data. Proteomics 2001;1 (2):340–9. link1

[37] Kammeijer GSM, Jansen BC, Kohler I, Heemskerk AAM, Mayboroda OA, Hensbergen PJ, et al. Sialic acid linkage differentiation of glycopeptides using capillary electrophoresis–electrospray ionization–mass spectrometry. Sci Rep 2017;7(1):3733. link1

[38] Anumula KR. Advances in fluorescence derivatization methods for highperformance liquid chromatographic analysis of glycoprotein carbohydrates. Anal Biochem 2006;350(1):1–23. link1

[39] Anumula KR, Dhume ST. High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. Glycobiology 1998;8(7):685–94. link1

[40] Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol 2019;15(6):346–66. link1

[41] Inazu T. New materials and techniques for glycomedicine. Int Congr Ser 2001;1223:91–5. link1

[42] Wang W. Glycomedicine: the current state of the art. Engineering. In press. link1

[43] Özdemir V, Arga KY, Aziz RK, Bayram M, Conley SN, Dandara C, et al. Digging deeper into precision/personalized medicine: cracking the sugar code, the third alphabet of life, and sociomateriality of the cell. OMICS J Integr Biol 2020;24(2):62–80. link1

[44] Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer 2021;1875(1):188464. link1

[45] Brasil S, Pascoal C, Francisco R, Marques-da-Silva D, Andreotti G, Videira PA, et al. CDG therapies: from bench to bedside. Int J Mol Sci 2018;19(5):1304. link1

[46] Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 2017;37(2–6):445–61. link1

[47] Doran RC, Tatsuno GP, O’Rourke SM, Yu B, Alexander DL, Mesa KA, et al. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. PLoS One 2018;13(4): e0196370. link1

[48] Breul J, Pickl U, Hartung R. Prostate-specific antigen in urine. Eur Urol 1994;26 (1):18–21. link1

[49] Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40(12):4658–62. link1

[50] Hsiao CJ, Tzai TS, Chen CH, Yang WH, Chen CH. Analysis of urinary prostatespecific antigen glycoforms in samples of prostate cancer and benign prostate hyperplasia. Dis Markers 2016;2016:8915809. link1

[51] Jankovic´ MM, Kosanovic´ MM. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem 2005;38(1):58–65. link1

[52] Xu M, Yang A, Xia J, Jiang J, Liu CF, Ye Z, et al. Protein glycosylation in urine as a biomarker of diseases. Transl Res 2023;253:95–107. link1

[53] Swiner DJ, Jackson S, Burris BJ, Badu-Tawiah AK. Applications of mass spectrometry for clinical diagnostics: the influence of turnaround time. Anal Chem 2020;92(1):183–202. link1

[54] Ombrone D, Giocaliere E, Forni G, Malvagia S, la Marca G. Expanded newborn screening by mass spectrometry: new tests, future perspectives. Mass Spectrom Rev 2016;35(1):71–84. link1

[55] Jannetto P. Therapeutic drug monitoring using mass spectrometry. In: Nair H, Clarke W, editors. Mass spectrometry for the clinical laboratory. London: Academic Press; 2017. p. 165–79. link1

[56] Volmer DA, Mendes LR, Stokes CS. Analysis of vitamin D metabolic markers by mass spectrometry: current techniques, limitations of the ‘‘gold standard” method, and anticipated future directions. Mass Spectrom Rev 2015;34 (1):2–23. link1

[57] Banerjee S. Empowering clinical diagnostics with mass spectrometry. ACS Omega 2020;5(5):2041–8. link1

[58] Zhang J, Rector J, Lin JQ, Young JH, Sans M, Katta N, et al. Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl Med 2017;9(406):eaan3968. link1

[59] Go S, Sato C, Yin J, Kannagi R, Kitajima K. Hypoxia-enhanced expression of free deaminoneuraminic acid in human cancer cells. Biochem Biophys Res Commun 2007;357(2):537–42. link1

[60] Nakata D, Münster AK, Gerardy-Schahn R, Aoki N, Matsuda T, Kitajima K. Molecular cloning of a unique CMP-sialic acid synthetase that effectively utilizes both deaminoneuraminic acid (KDN) and N-acetylneuraminic acid (Neu5Ac) as substrates. Glycobiology 2001;11(8):685–92. link1